A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Fracture
- Focus Therapeutic Use
- 14 Sep 2018 According to a Bone Therapeutics media release, the company expects to submit the Clinical Trial Application (CTA) for the trial in second half of 2019.
- 24 Jan 2018 New trial record
- 23 Jan 2018 According to a Bone Therapeutics media release, preparation has been initiated and the start of the study is anticipated in the second half of 2018.